

Results achieved with ZORYVE (roflumilast) topical foam, 0.3% in the pivotal Phase 3 STRATUM trial

Scalp




Baseline

IGA = 4



Week 2

IGA = 2



Week 8

IGA = 1


Actual clinical trial patient



The primary efficacy endpoint was Investigator Global Assessment (IGA) Success at week 8, defined as IGA of 0 (Clear) or 1 (Almost Clear) plus ≥ 2 -point improvement from baseline.

Results achieved with ZORYVE (roflumilast) topical foam, 0.3% in the pivotal Phase 3 STRATUM trial

Face



Actual clinical trial patient



The primary efficacy endpoint was Investigator Global Assessment (IGA) Success at week 8, defined as IGA of 0 (Clear) or 1 (Almost Clear) plus ≥ 2 -point improvement from baseline.